Ocugen (OCGN) Rising Before Q2 Financial Results Out

As everything becomes digital eyes become vulnerable to blindness diseases. Ocugen’s (NASDAQ: OCGN) mission is to discover new ways 0f blindness treatment. Even genetic therapy could aid the company in healing customers’ eyes.

While most of the biotech stocks rise via positive news in treating COVID-19 patients, OCGN surges due to other news that is linked to only blindness treatment. The revenue also comes from bio pharmacy products sold in drug stores.

OCGN is so cheap as newbies with several thousand dollars may get tens of thousands of shares. Friday’s $0.55 may soon turn to $2 or $3 or even more amid many short term traders are looking for cheap and reliable stock.

Richard McEntire

Finance and Entertainment Reporter Richard is a bottle of wine - the older the sweeter. He has already found the sweetest hobby in writing entertainment and finance news for Own Snap. Readers get the updated posts regularly from him searching for real-time news.